National guidelines for diagnosis and treatment of breast cancer 2022 in China (English version).
作者信息
Health Commission Of The People's Republic Of China National
出版信息
Chin J Cancer Res. 2022 Jun 30;34(3):151-175. doi: 10.21147/j.issn.1000-9604.2022.03.02.
Abstract
摘要
相似文献
1
National guidelines for diagnosis and treatment of breast cancer 2022 in China (English version).《中国2022年乳腺癌诊疗规范（英文版）》
Chin J Cancer Res. 2022 Jun 30;34(3):151-175. doi: 10.21147/j.issn.1000-9604.2022.03.02.
2
Comments on .关于……的评论
Chin J Cancer Res. 2022 Oct 30;34(5):451-452. doi: 10.21147/j.issn.1000-9604.2022.05.03.
3
National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version).《中国国家卫生健康委员会结直肠癌诊疗规范（2023年版）》（英文版）
Chin J Cancer Res. 2023 Jun 30;35(3):197-232. doi: 10.21147/j.issn.1000-9604.2023.03.01.
4
Comments on .关于……的评论
Chin J Cancer Res. 2023 Oct 30;35(5):431-432. doi: 10.21147/j.issn.1000-9604.2023.05.01.
5
National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version).《中国结直肠癌诊疗规范（2020年版）》英文版本
Chin J Cancer Res. 2020 Aug;32(4):415-445. doi: 10.21147/j.issn.1000-9604.2020.04.01.
6
National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version).《中国2022年甲状腺癌诊疗规范（英文版）》
Chin J Cancer Res. 2022 Jun 30;34(3):131-150. doi: 10.21147/j.issn.1000-9604.2022.03.01.
7
National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version).《中国2022年胃癌诊疗规范（英文版）》
Chin J Cancer Res. 2022 Jun 30;34(3):207-237. doi: 10.21147/j.issn.1000-9604.2022.03.04.
8
National guidelines for diagnosis and treatment of cervical cancer 2022 in China (English version).《中国2022年宫颈癌诊疗国家指南》（英文版）
Chin J Cancer Res. 2022 Jun 30;34(3):256-269. doi: 10.21147/j.issn.1000-9604.2022.03.06.
9
National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version).《2022年中国胰腺癌诊疗指南》（英文版）
Chin J Cancer Res. 2022 Jun 30;34(3):238-255. doi: 10.21147/j.issn.1000-9604.2022.03.05.
10
National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version).《中国2022年肺癌诊疗国家指南》（英文版）
Chin J Cancer Res. 2022 Jun 30;34(3):176-206. doi: 10.21147/j.issn.1000-9604.2022.03.03.
引用本文的文献
1
Knowledge, attitude, and practice among non-breast cancer women towards breast cancer screening with a focus on economic factors.非乳腺癌女性对乳腺癌筛查的认知、态度和行为，重点关注经济因素。
Sci Rep. 2025 Aug 14;15(1):29854. doi: 10.1038/s41598-025-15478-8.
2
Establishment and Partial Characterization of Canine Mammary Tumor Cell Lines.犬乳腺肿瘤细胞系的建立及部分特性研究
Animals (Basel). 2025 Jul 7;15(13):1991. doi: 10.3390/ani15131991.
3
Efficacy of Pyrotinib combined with Trastuzumab in the treatment of patients with human epidermal growth factor receptor-2 positive breast cancer.吡咯替尼联合曲妥珠单抗治疗人表皮生长因子受体2阳性乳腺癌患者的疗效
Pak J Med Sci. 2025 Jun;41(6):1749-1754. doi: 10.12669/pjms.41.6.11682.
4
A Review of Breast Cancer Surgeries in a Sub-urban Nigerian Tertiary Hospital and the Limitations of Breast-Conserving Surgery.尼日利亚一家城郊三级医院的乳腺癌手术综述及保乳手术的局限性
Breast Cancer (Auckl). 2025 Mar 12;19:11782234251323774. doi: 10.1177/11782234251323774. eCollection 2025.
5
Multi-institutional evaluation comparing guidance from International Ki67 Working Group vs National Health Commission of China on immunohistochemistry-based Ki67 assessment alongside the Quantitative Dot Blot method.多机构评估：比较国际Ki67工作组与中国国家卫生健康委员会关于基于免疫组织化学的Ki67评估以及定量斑点印迹法的指导意见。
Front Oncol. 2025 Jan 27;14:1510273. doi: 10.3389/fonc.2024.1510273. eCollection 2024.
6
Occult breast cancer in an older woman: A case report.老年女性隐匿性乳腺癌：一例病例报告。
Exp Ther Med. 2024 Dec 24;29(2):38. doi: 10.3892/etm.2024.12788. eCollection 2025 Feb.
7
Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial.注射用英特他单抗联合长春瑞滨每周或每三周治疗HER2阳性转移性乳腺癌：一项多中心、随机、II期临床试验。
J Transl Int Med. 2024 Nov 6;12(5):466-477. doi: 10.1515/jtim-2024-0022. eCollection 2024 Nov.
8
Sacituzumab govitecan in HRHER2 metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.戈沙妥珠单抗治疗激素受体和人表皮生长因子受体2均为阴性的转移性乳腺癌：随机3期EVER-132-002试验
Nat Med. 2024 Dec;30(12):3709-3716. doi: 10.1038/s41591-024-03269-z. Epub 2024 Oct 1.
9
Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring.HER2靶向PET/CT成像在乳腺癌患者中的影响及治疗反应监测
Oncologist. 2025 Jan 17;30(1). doi: 10.1093/oncolo/oyae188.
10
Zotero 插件